Lahjavida Bio Accepted to Present Tumor-Targeted Small-Molecule Drug Delivery Platform at AACR Annual Meeting 2026
Lahjavida’s Dye-Drug Conjugates (DDCs) are small-molecule “dye–linker–payload” constructs, conceptually analogous to antibody-drug conjugates (ADCs), which are composed of an antibody, linker, and cytotoxic payload. Like ADCs, DDCs are designed to improve the therapeutic index of potent cancer therapies through targeted delivery. However, DDCs leverage small-molecule dye chemistry rather than antibodies to enable tumor-selective uptake.
“We are honored to have our work selected for presentation at AACR, one of the most respected scientific forums in oncology,” said Lyle Small, Founder and Chief Executive Officer of Lahjavida Bio. “AACR brings together leaders across cancer biology, drug discovery, and translational science, and we look forward to engaging with the community around our approach to tumor-selective drug delivery.”
In accordance with AACR’s media and embargo policies, no additional details from the abstract will be disclosed prior to its official publication and presentation at the meeting.
To learn more about Lahjavida Bio and its Dye-Drug Conjugate platform, visit https://lahjavida.com.
Investor Relations Contact:
Sidharth Mehta
Allele Capital Partners
smehta@allelecapital.com
Media Contact:
Madelyn De Los Santos
Putnam Insights LLC
madelyn@putnaminsights.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
